Compounds > crolibulin
Page last updated: 2024-11-13

crolibulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

crolibulin: a vascular disrupting agent with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23649181
CHEMBL ID2103852
CHEBI ID177518
SCHEMBL ID1750575
MeSH IDM000606950

Synonyms (34)

Synonym
1000852-17-4
CHEBI:177518
(4r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile
crolibulin
D09882
crolibulin (usan)
crolibulin [usan:inn]
9ent43ky91 ,
epc2407
unii-9ent43ky91
epc 2407
CHEMBL2103852
epc-2407
crolibulin [usan]
crolibulin [who-dd]
crolibulin [inn]
SCHEMBL1750575
DTXSID10142925
4h-1-benzopyran-3-carbonitrile, 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-, (4r)-;4h-1-benzopyran-3-carbonitrile, 2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-, (4r)-
DB12925
(r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene-3-carbonitrile
HY-13603
CS-0007407
EX-A2452
crolibulin; epc2407
JXONINOYTKKXQQ-CQSZACIVSA-N
(r)-2,7,8-triamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4h-chromene
(4r)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4h-1-benzopyran-3-carbonitrile
bg0 ,
epc2407; crinobulin
Q27272449
MS-27274
AC-36076
AKOS040741574
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
neoflavonoidAny 1-benzopyran with an aryl substituent at position 4. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1352574Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4.
AID1352573Antiproliferative activity against human H460 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4.
AID1352572Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4.
AID1352576Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4.
AID1352575Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.43 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		2.1710pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.1710alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
gadolinium
Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.		3.6411f-block element atom;
lanthanoid atom
carbogen
carbogen: mixture of 95% O2 & 5% CO2		2.1110
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.1710stilbene
fosbretabulin
[no description available]		2.1710stilbenoid
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.6411
Angiogenesis, Pathologic
[description not available]		03.9521
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		15.6411
Carcinoma, Epidermoid
[description not available]		02.1110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.1110
Cancer of Prostate
[description not available]		02.1110
Androgen-Independent Prostatic Cancer
[description not available]		02.1110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1110
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		02.1110
Benign Neoplasms, Brain
[description not available]		02.1310
Glial Cell Tumors
[description not available]		02.1310
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.1310
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.1310